Logo

Roche received the EU’s CHMP Positive Opinion for subcutaneous injection of Tecentriq to treat multiple types of cancer

Share this

Roche received the EU’s CHMP Positive Opinion for subcutaneous injection of Tecentriq to treat multiple types of cancer

Shots:

  • The EU’s CHMP had adopted positive opinion for the approval of Tecentriq based on Phase IB/III (IMscin001) study evaluating PK, safety & efficacy of the Tecentriq SC, vs Tecentriq IV, in treated locally advanced or metastatic NSCLC patients (n=371) who have failed prior platinum therapy
  • The result demonstrated consistency in efficacy measured by OS with median follow up of 9.5mos., PFS & ORR and safety, in both formulation, additionally exhibiting equivalent levels of Tecentriq in the blood over a particular dosage interval based on known PK parameters
  • Tecentriq SC, which has got its first marketing authorization in the UK is the mAb that binds to the PD-L1, & blocks its interactions with both the PD-1 and B7.1 receptors

Ref: Globenewswire | Image: Roche

Related News:- Genentech Reports Second Interim Analysis Results from the P-III Study (SKYSCRAPER-01) of Tiragolumab + Tecentriq for PD-L1-High Metastatic Non-Small Cell Lung Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions